Roberta Lorenzon
University of Paris
ImmunologyInterleukin 2FOXP3MedicineIL-2 receptor
What is this?
Publications 7
Commenting on Meyer et al 1 our recent publication2 ‘Immunological and clinical effects of low-dose interleukin-2 (IL-2) across 11 autoimmune diseases in a single, open clinical trial’, Dr Meyer and colleagues point to the issue of concomitant background therapies that could affect the effects of low-dose IL-2. They reported a significant increase of Treg cell frequencies in peripheral blood of patients with rheumatoid arthritis treated with methotrexate, adalimumab, etanercept, golimumab and to...
Objective Regulatory T cells (Tregs) prevent autoimmunity and control inflammation. Consequently, any autoimmune or inflammatory disease reveals a Treg insufficiency. As low-dose interleukin-2 (ld-IL2) expands and activates Tregs, it has a broad therapeutic potential. Aim We aimed to assess this potential and select diseases for further clinical development by cross-investigating the effects of ld-IL2 in a single clinical trial treating patients with 1 of 11 autoimmune diseases. Methods We perfo...
22 CitationsSource
#1Guillaume Churlaud (University of Paris)H-Index: 8
#2Chadi Abbara (University of Angers)H-Index: 4
Last. David Klatzmann (University of Paris)H-Index: 63
view all 9 authors...
2 CitationsSource
#1Roberta LorenzonH-Index: 3
#2Encarnita Mariotti-Ferrandiz (University of Paris)H-Index: 5
Last. David KlatzmannH-Index: 63
view all 29 authors...
Introduction Autoimmune and autoinflammatory diseases (AIDs) represent a socioeconomic burden as the second cause of chronic illness in Western countries. In this context, the TRANSIMMUNOM clinical protocol is designed to revisit the nosology of AIDs by combining basic, clinical and information sciences. Based on classical and systems biology analyses, it aims to uncover important phenotypes that cut across diagnostic groups so as to discover biomarkers and identify novel therapeutic targets. Me...
1 CitationsSource
#1Roberta Lorenzon (University of Paris)H-Index: 3
#2Iannis Drakos (University of Paris)H-Index: 1
Last. Encarnita Mariotti-Ferrandiz (University of Paris)H-Index: 5
view all 25 authors...
Objectives: Autoimmune and inflammatory diseases (AIDs) form a continuum of autoimmune and inflammatory diseases, yet AIDs' nosology is based on syndromic classification. The TRANSIMMUNOM trial (NCT02466217) was designed to re-evaluate AIDs nosology through clinic-biological and multi-omics investigations of patients with one of 19 selected AIDs. To allow cross-analyses of clinic-biological data together with omics data, we needed to integrate clinical data in a harmonized database. Materials an...
#1Guillaume Churlaud (French Institute of Health and Medical Research)H-Index: 8
#2Fabien Pitoiset (French Institute of Health and Medical Research)H-Index: 8
Last. David Klatzmann (French Institute of Health and Medical Research)H-Index: 63
view all 7 authors...
In addition to CD4+ regulatory T cells (Tregs), CD8+ suppressor T cells are emerging as an important subset of regulatory T cells. Diverse populations of CD8+ T cells with suppressive activities have been described. Among them, a small population of CD8+CD25+FOXP3+ T cells is found both in mice and humans. In contrast to thymic-derived CD4+CD25+FOXP3+ Tregs, their origin and their role in the pathophysiology of autoimmune diseases (AIDs) are less understood. We report here the number, phenotype,...
74 CitationsSource
#1Michelle Rosenzwajg (French Institute of Health and Medical Research)H-Index: 29
#2Guillaume Churlaud (French Institute of Health and Medical Research)H-Index: 8
Last. David Klatzmann (French Institute of Health and Medical Research)H-Index: 63
view all 16 authors...
Most autoimmune diseases (AID) are linked to an imbalance between autoreactive effector T cells (Teffs) and regulatory T cells (Tregs). While blocking Teffs with immunosuppression has long been the only therapeutic option, activating/expanding Tregs may achieve the same objective without the toxicity of immunosuppression. We showed that low-dose interleukin-2 (ld-IL-2) safely expands/activates Tregs in patients with AID, such HCV-induced vasculitis and Type 1 Diabetes (T1D). Here we analyzed the...
92 CitationsSource